The overall goal of this SCOR proposal is to develop and conduct clinical trials to correct congenital diseases of the human hematopoietic stem cell. The central theme of the research plan is the development of new methods of cellular and transduction gene therapy for these diseases. Specifically, we will develop new methods for stem cell transplantation across HLA barriers and will attempt to treat Fanconi Anemia and Diamond-Blackfan Anemia by replacement gene therapy protocols for these diseases. Dr. Guinan's project will focus on new advances in the biological and clinical aspects of haplomismatch bone marrow transplantation. Several projects will focus on the basic biology of Fanconi Anemia and Diamond- Blackfan Anemia and on Retroviral Transfection Scale-Up and Phase I gene therapy protocols for bone marrow transplantation. Other projects will focus on the continued development of retroviral and lentiviral programs which fortify our clinical efforts. In Dr. Mulligan's project, the capacity of bone marrow stem cells to replace diseased muscle cells will be explored while Dr. Sodroski's project will investigate the adaptations of HIV that will permit the virus access to human cells. The strength of this proposal lies in its focused drive toward clinical experimentation while gathering data of basic importance and exploring new frontiers.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Specialized Center (P50)
Project #
2P50HL054785-06
Application #
6221314
Study Section
Special Emphasis Panel (ZHL1-CSR-C (S1))
Project Start
1995-09-30
Project End
2005-08-31
Budget Start
2000-11-01
Budget End
2001-08-31
Support Year
6
Fiscal Year
2000
Total Cost
$1,705,452
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
149617367
City
Boston
State
MA
Country
United States
Zip Code
02215
Huang, Min; Kennedy, Richard; Ali, Abdullah M et al. (2011) Human MutS and FANCM complexes function as redundant DNA damage sensors in the Fanconi Anemia pathway. DNA Repair (Amst) 10:1203-12
Chen, Clark C; Kennedy, Richard D; Sidi, Samuel et al. (2009) CHK1 inhibition as a strategy for targeting Fanconi Anemia (FA) DNA repair pathway deficient tumors. Mol Cancer 8:24
Kee, Younghoon; Kim, Jung Min; D'Andrea, Alan D et al. (2009) Regulated degradation of FANCM in the Fanconi anemia pathway during mitosis. Genes Dev 23:555-60
Mirchandani, Kanchan D; McCaffrey, Ryan M; D'Andrea, Alan D (2008) The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly. DNA Repair (Amst) 7:902-11
Davies, Jeff K; Gribben, John G; Brennan, Lisa L et al. (2008) Outcome of alloanergized haploidentical bone marrow transplantation after ex vivo costimulatory blockade: results of 2 phase 1 studies. Blood 112:2232-41
Ansen, Sascha; Butler, Marcus O; Berezovskaya, Alla et al. (2008) Dissociation of its opposing immunologic effects is critical for the optimization of antitumor CD8+ T-cell responses induced by interleukin 21. Clin Cancer Res 14:6125-36
Kennedy, Richard D; Chen, Clark C; Stuckert, Patricia et al. (2007) Fanconi anemia pathway-deficient tumor cells are hypersensitive to inhibition of ataxia telangiectasia mutated. J Clin Invest 117:1440-9
Butler, Marcus O; Lee, Jeng-Shin; Ansen, Sascha et al. (2007) Long-lived antitumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. Clin Cancer Res 13:1857-67
Li, Xing; Gold, Bert; O'hUigin, Colm et al. (2007) Unique features of TRIM5alpha among closely related human TRIM family members. Virology 360:419-33
Wang, Xiaozhe; Kennedy, Richard D; Ray, Kallol et al. (2007) Chk1-mediated phosphorylation of FANCE is required for the Fanconi anemia/BRCA pathway. Mol Cell Biol 27:3098-108

Showing the most recent 10 out of 88 publications